Press release
Hypercholesterolemia Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in Hypercholesterolemia Research. Learn more about our innovative pipeline today! @ Hypercholesterolemia Pipeline Outlook [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hypercholesterolemia Pipeline Report
* In July 2025, Merck Sharp & Dohme LLC announced a study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
* DelveInsight's Hypercholesterolemia pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Hypercholesterolemia treatment.
* The leading Hypercholesterolemia Companies such as Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics and others.
* Promising Hypercholesterolemia Pipeline Therapies such as Gemcabene, Rosuvastatin calcium, KJX839, statins, ezetimibe, MK-0524A, ER Niacin and others.
Stay informed about the cutting-edge advancements in Hypercholesterolemia treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Hypercholesterolemia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hypercholesterolemia Emerging Drugs Profile
* MK-0616: Merck Sharp & Dohme LLC
MK-0616 is an investigational, potentially first oral PCSK9 inhibitor designed to lower low density lipoprotein (LDL) cholesterol. Discovered and developed by Merck, MK-0616 is a macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors. MK-0616 is being developed under an agreement with UCB Pharmaceuticals. Results from the Phase IIb clinical trial evaluating MK-0616 showed that MK-0616 was generally well-tolerated with no overall trends across treatment groups in discontinuation rates or adverse events at week 16. No serious adverse events that were considered by the investigator to be related to treatment with MK-0616 were reported. Currently the drug is in Phase III stage for the treatment of Hypercholesterolemia.
* ARO-ANG 3: Arrowhead Pharmaceuticals
ARO-ANG3 is an investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), a hepatocyte expressed regulator of lipid and lipoprotein metabolism with multiple potential modes of action, including inhibition of lipoprotein lipase and endothelial lipase. Given the inhibitory role of ANGPTL3 in the metabolism of various lipoproteins and triglycerides, reduced expression and reduced circulating levels of ANGPTL3 may increase clearance of LDL-cholesterol, HDL-cholesterol, and triglycerides. Currently the drug is in Phase II stage for the treatment of Hypercholesterolemia.
* VXX-401: Vaxxinity, Inc.
VXX-401 was designed using Vaxxinity's proprietary synthetic peptide vaccine platform and is being developed for the treatment of hypercholesterolemia. The platform is designed to harness the immune system to convert the body into its own natural "drug factory," stimulating the production of antibodies. VXX-401 is designed to induce robust, long-acting antibodies against PCSK9 and lower LDL cholesterol to prevent or treat coronary heart disease. Currently the drug is in Phase I stage for the treatment of Hypercholesterolemia.
The Hypercholesterolemia Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Hypercholesterolemia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypercholesterolemia Treatment.
* Hypercholesterolemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hypercholesterolemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypercholesterolemia market.
Learn more about Hypercholesterolemia Drugs opportunities in our groundbreaking Hypercholesterolemia research and development projects @ Hypercholesterolemia Unmet Needs [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hypercholesterolemia Companies
Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics and others.
Hypercholesterolemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Hypercholesterolemia Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Hypercholesterolemia treatment by visiting our website. Stay informed about how we're transforming the future of Cardiovascular Diseases @ Hypercholesterolemia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hypercholesterolemia Pipeline Report
* Coverage- Global
* Hypercholesterolemia Companies- Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics and others.
* Hypercholesterolemia Pipeline Therapies- Gemcabene, Rosuvastatin calcium, KJX839, statins, ezetimibe, MK-0524A, ER Niacin and others.
* Hypercholesterolemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hypercholesterolemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Hypercholesterolemia Pipeline on our website @ Hypercholesterolemia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hypercholesterolemia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hypercholesterolemia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* MK-0616: Merck Sharp & Dohme LLC
* Mid Stage Products (Phase II)
* ARO-ANG 3: Arrowhead Pharmaceuticals
* Early Stage Products (Phase I)
* VXX-401: Vaxxinity, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Hypercholesterolemia Key Companies
* Hypercholesterolemia Key Products
* Hypercholesterolemia- Unmet Needs
* Hypercholesterolemia- Market Drivers and Barriers
* Hypercholesterolemia- Future Perspectives and Conclusion
* Hypercholesterolemia Analyst Views
* Hypercholesterolemia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypercholesterolemia-pipeline-appears-robust-with-25-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hypercholesterolemia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypercholesterolemia Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4103579 • Views: …
More Releases from ABNewswire
Your Quality Pressure Washing Expands Fleet to Meet Houston's High Demand for Pr …
The need for professional pressure washing Houston services is particularly high due to the city's humid, subtropical climate. This environment accelerates the growth of mold, mildew, and algae on exterior surfaces, while constant construction in the growing metropolitan area creates additional dust and grime.
In response to growing demand for professional exterior cleaning solutions, Your Quality Pressure Washing Houston has announced a significant expansion of its service fleet. This strategic investment…
Market Outlook Projects Steady Growth for Luxury Custom Home Builders in 2025
As families invest in properties that reflect their lifestyle and long-term goals, the role of custom home builders in Gulf Shores AL grows increasingly vital.
The demand for luxury custom home builders [https://ddandbllc.com/custom-home-pool-builder-gulf-shores-al/] continues to rise across the United States, with Gulf Shores, AL, emerging as a key market for homeowners seeking elegance, comfort, and modern design. While many search for home builders near me, the region shows strong momentum fueled…
Desman Orthodontics Launches "Smiles for Students" Scholarship Orthodonist Servi …
For many families in the area, finding a trusted local provider is a priority. As an established orthodontist Port St Lucie families have relied on for years, Desman Orthodontics is uniquely positioned to understand the needs of the community. The practice's decision to create this scholarship stems from a recognition that a healthy, confident smile can have a profound impact on a young person's social development and self-esteem, yet it…
Lone Wolf Roofing Strengthens Its Presence in LaPlace As the Top Roofer in LaPla …
Lone Wolf Roofing is the best roofer in LaPlace Louisiana.
Image: https://www.abnewswire.com/upload/2025/09/d18162e78e8b91dcdbe94df43778e8d2.jpg
Lone Wolf Roofing, a premier Louisiana-based roofing company, today announced the expansion of its services in LaPlace, offering homeowners and businesses access to unmatched craftsmanship, a 100-Year Warranty, and an unprecedented promise: if installation does not begin within 24 hours of signing, the roof is free.
With Louisiana communities facing recurring storms, unpredictable weather, and high roofing costs, Lone Wolf Roofing's…
More Releases for Hypercholesterolemia
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Hypercholesterolemia Treatment Market Reviews Analysis Report 2024
Hypercholesterolemia Treatment Market to reach over USD 36.37 billion by the year 2031 - Exclusive Report by InsightAce Analytic
According to a new report by InsightAce Analytic, the "Hypercholesterolemia Treatment Market" in terms of revenue was estimated to be worth $27.9 billion in 2023 and is poised to reach $36.37 billion by 2031, growing at a CAGR of 3.43% from 2024 to 2031.
Get a free Sample copy of the…
Hypercholesterolemia Treatment Market: Transforming Lives: Impact of Hypercholes …
Newark, New Castle, USA: The "Hypercholesterolemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypercholesterolemia Treatment Market: https://www.growthplusreports.com/report/hypercholesterolemia-treatment-market/8571
This latest report researches the industry structure, sales, revenue,…
Hypercholesterolemia Treatment Market Insights, Forecast to 2031
The report extensively examines the global Hypercholesterolemia Treatment market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hypercholesterolemia Treatment . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Hypercholesterolemia Market Global Analysis & 2023 Forecast Report
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol…
